Margaret Brimble

Prof. Margaret Brimble

The University of Auckland
orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Nature Reviews Methods Primers
Verified
Journal Article
Closed access
PDF file
TRTorben Rogge
Torben Rogge
NKNikolaos Kaplaneris
Nikolaos Kaplaneris
NCNaoto Chatani
Naoto Chatani
JKJinwoo Kim
Jinwoo Kim
SCSukbok Chang
Sukbok Chang
LALutz Ackermann
Lutz Ackermann

21 August 2014 in Chemical Reviews
Verified
Journal Article
Open access
ANAnaïs F. M. Noisier
Anaïs F. M. Noisier
MBMargaret Brimble
Margaret Brimble

27 September 2021 in Molecules
Verified
Journal Article
Open access
PDF file
JTJuliana Tong
Juliana Tong
Paul William Richard HarrisPaul William Richard Harris
Paul William Richard Harris
MBMargaret Brimble
Margaret Brimble
Iman KavianiniaIman Kavianinia
Iman Kavianinia
The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemic, 2020 was a landmark year for deals and partnerships in the ADC arena, suggesting that there remains significant interest from Big Pharma. Herein we review the enthusiasm for ADCs by focusing on the features of those approved by the FDA, and offer some thoughts as to where the field is headed.

1 October 2019 in Current Opinion in Chemical Biology
Verified
Journal Article
Closed access
EDEmma Kathleen Davison
Emma Kathleen Davison
MBMargaret Brimble
Margaret Brimble

7 December 2020 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
LGLiqian Gao
Liqian Gao
WWWei Wang
Wei Wang
XWXuan Wang
Xuan Wang
FYFen Yang
Fen Yang
LXLiuxing Xie
Liuxing Xie
SYShao Q. Yao
Shao Q. Yao
Parkinson's disease (PD), as the second most common neurodegenerative disease, is caused by complex pathological processes and currently remains very difficult to treat. PD brings great distress to patients and imposes a heavy economic burden on society. The number of PD patients is growing as the aging population increases worldwide. Therefore, it is crucial to develop new tools for aiding the early diagnosis and treatment of PD. The significant pathological features involved in PD include the abnormal accumulation of α-synuclein, metal ion dyshomeostasis, oxidative stress, mitochondrial dysfunction and neurotransmitter deficiencies. In recent years, fluorescent probes have emerged as a powerful bioimaging tool with potential to help understand the pathological processes of PD via the detection and monitoring of pathological features. In this review, we comprehensively summarize the design and working mechanisms of fluorescent probes along with their applications in the detection of various PD biomarkers. We also discuss the current limitations of fluorescent probes and provide perspectives on how these limitations can be overcome to develop better fluorescent probes suitable for application in clinical trials in the future. We hope that this review provides valuable information and guidance for the development of new fluorescent probes that can be used clinically in the early diagnosis of PD and contributes to the development of efficient PD drugs in the future.

4 March 2010 in Natural Product Reports
Verified
Journal Article
Closed access
PDF file
Jon SperryJon Sperry
Jon Sperry
ZWZoe E. Wilson
Zoe E. Wilson
DRDominea C. K. Rathwell
Dominea C. K. Rathwell
MBMargaret Brimble
Margaret Brimble
Covering: up to late 2009 A review of the isolation, biological activity and synthesis of natural products containing a benzannulated spiroketal moiety is provided.